Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Alx Oncology Holdings (ALXO) EPS (Basic) (2019 - 2023)

Alx Oncology Holdings' EPS (Basic) history spans 5 years, with the latest figure at -$0.92 for Q4 2023.

  • For Q4 2023, EPS (Basic) fell 22.67% year-over-year to -$0.92; the TTM value through Dec 2023 reached -$3.74, down 23.43%, while the annual FY2025 figure was -$1.9, 26.36% up from the prior year.
  • EPS (Basic) for Q4 2023 was -$0.92 at Alx Oncology Holdings, up from -$1.24 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.35 in Q1 2021 and bottomed at -$4.41 in Q2 2020.
  • The 5-year median for EPS (Basic) is -$0.81 (2022), against an average of -$1.17.
  • The largest annual shift saw EPS (Basic) plummeted 162.5% in 2020 before it skyrocketed 90.93% in 2021.
  • A 5-year view of EPS (Basic) shows it stood at -$2.83 in 2019, then surged by 82.33% to -$0.5 in 2020, then tumbled by 42.0% to -$0.71 in 2021, then dropped by 5.63% to -$0.75 in 2022, then decreased by 22.67% to -$0.92 in 2023.
  • Per Business Quant, the three most recent readings for ALXO's EPS (Basic) are -$0.92 (Q4 2023), -$1.24 (Q3 2023), and -$0.84 (Q2 2023).